Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Huang, Dongsheng ^a   Duan, Hongying ^a,c   Huang, Hao ^b   Tong, Xiangmin ^a   Han, Yong ^a   Ru, Guoqing ^a   Qu, Like ^b   Shou, Chengchao ^b   Zhao, Zhongsheng ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2-METHOXY-N-(3-(4-((3-METHYL-4-((6-METHYL-3-PYRIDINYL)OXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2-PROPENYL)ACETAMIDE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TRANSCRIPTION FACTOR SNAIL;

CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL ANALYSIS; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; SNAIL FAMILY TRANSCRIPTION FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84957557765     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20502     Document Type: Article

References (55)

1. Parkin, D. M., Pisani, P., Ferlay, J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80, 827-841 (1999).
2. Hohenberger, P., Gretschel, S. Gastric cancer. Lancet 362, 305-315 (2003).
3. Zhang, D., Fan, D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 6, 527-537 (2010).
4. Rosenberg, B., VanCamp, L., Trosko, J. E., Mansour, V. H. Platinum compounds: a new class of potent antitumour agents. Nature 222, 385-386 (1969).
5. Kang, Y. K. et al. Capecitabine/Cisplatin Versus 5-Fluorouracil/Cisplatin as First-line Therapy in Patients with Advanced Gastric Cancer: A Randomised Phase III Non inferiority Trial. Ann Oncol 20, 666-673 (2009).
6. Yu, P. F. et al. Significance of multidrug resistance gene-associated proteins in the postoperative adjuvant chemotherapy for gastric carcinoma and the prognosis. Zhonghua Wei Chang Wai Ke Za Zhi 13, 289-293 (2010).
7. Scheffer, G. L. et al. The drug resistace-related protein LRP is the vault protein. Nature Med 1, 578-582 (1995).
8. Hu, W. Q., Peng, C. W., Li, Y. The expression and significance of P-glycoprotein, lung resistance protein and multi-drug-resistanceassociated protein in gastric cancer. Exp Clin Cancer Res 28, 144 (2009).
9. Gianni, L. Anthracycline resistance: the problem and its current definition. Semin Oncol 24, 10-17 (1997).
10. Hay, E. D. An overview of epithelio-mesenchymal transformation. Acta Anat 154, 8-20 (1995).
11. Kalluri, R., Weinberg, R. A. The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420-1428 (2009).
12. Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
13. López-Novoa, J. M., Nieto, M. A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1, 303-314 (2009).
14. Keshamouni, V. G., Schiemann, W. P. EMT in Tumor Metastasis: A Method to the Madness. Future Oncol 8, 1109-1111 (2009).
15. Scheel, C., Weinberg, R. A. Cancer stem cells and epithelial mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22, 396-403 (2012).
16. Wang, X. et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23, 474-482 (2004).
17. Yang, A. D. et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12, 4147-4153 (2006).
18. Kajiyama, H. et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31, 277-283 (2007).
19. Shah, A. N. et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14, 3629-3637 (2007).
20. Mendelsohn, J., Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000).
21. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
22. Kaptain, S., Tan, L. K., Chen, B. Her-2/neu and breast cancer. Diagn Mol Pathol 10, 139-152 (2001).
23. Nahta, R. Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012, 428062 (2012). doi: 10.5402/2012/428062.
24. Goldenberg, M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21, 309-318 (1999).
25. Schuell, B., Gruenberger, T., Scheithauer, W., Zielinski, C. H., Wrba, F. HER 2/neu protein expression in colorectal cancer. BMC Cancer 8, 123 (2006).
26. Eltze, E. et al. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 26, 1525-1531 (2005).
27. McKenzie, S. J. et al. Serum levels of HER-2 neu (C-erbB-correlate with overexpression of p185neu in human ovarian cancer. Cancer 71, 3942-3946 (1993).
28. Hetzel, D. J. et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47, 179-185 (1992).
29. Hirashima, N., Takahashi, W., Yoshii, S., Yamane, T., Ooi, A. Protein overexpression and gene amplificationof c-erbB-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 14, 556-662 (2001).
30. Mitra, A. B., Murty, V. V., Pratap, M., Sodhani, P., Chaganti, R. S. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54, 637-639 (1994).
31. Beckhardt, R. N. et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 121, 1265-1270 (1995).
32. Reichelt, U. et al. Frequent homogenous HER-2 amplification in primary and metastatic adenocarcinomas of the esophagus. Mod Path 20, 120-129 (2007).
33. Lemoine, N. R. et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 64, 79-83 (1991).
34. Gravalos, C., Jimeno, A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19, 1523-1529 (2008).
35. Boku, N. Her2-positive gastric cancer. Gastric Cancer 17, 1-12 (2014).
36. Shin, N. R. et al. Overexpression of Snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. BMC Cancer 12, 521 (2012).
37. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917 (2010).
38. Tanner, M. et al. Topoisomerase Ilalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer. J Clin Oncol 24, 2428-2436 (2006).
39. Cho, H. J. et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer 135, 1553-1563 (2014).
40. Cho, H. J. et al. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett 311, 48-56 (2011).
41. Thiery, J. P., Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7, 131-142 (2006).
42. Huber, M. A. et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114, 569-581 (2004).
43. Lamouille, S., Xu, J., Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15, 178-196 (2014).
44. Yang, J., Weinberg, R. A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 14, 818-829 (2008).
45. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20, 719-726 (2002).
46. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353, 1673-1684 (2005).
47. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
48. Fujimoto-Ouchi, K. et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59, 795-805 (2007).
49. Yu, G. Z., Chen, Y., Wang, J. J. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship withclinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 135, 1331-1339 (2009).
50. Kim, H. K. et al. A Gene Expression Signature of Acquired Chemoresistance to Cisplatin and Fluorouracil Combination Chemotherapy in Gastric Cancer Patients. PLoS ONE 6, e16694 doi: 10.1371/journal.pone.0016694 (2011).
51. Wang, Z. H. et al. Establishment and preliminary observation on biological characteristics of human gastric Mucinous adenocarcinoma cell line MGC803. Acta Biologiae Experimentalis Sinica 16, 257-262 (1983).
52. Huang, H. et al. Establishment of drug resistant cell line of MGC803 and analysis of differential secretome. Beijing Da Xue Xue Bao 46, 183-189 (2014).
53. Duan, H., Qu, L., Shou, C. Mycoplasma hyorhinis induces epithelial-mesenchymal transition in gastric cancer cell MGC803 via TLR4-NF-? B signaling. Cancer Lett 354, 447-454 (2014).
54. Hillig, T. et al. Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer. APMIS 120, 1000-1007 (2012).
55. Duan, H. Y. et al. Mycoplasma hyorhinis infection promotes NF-? B-dependent migration of gastric cancer cells. Cancer Res 74, 5782-5794 (2014).